I am a
Home I AM A Search Login

Papers of the Week


2022 Feb 24


Inflammopharmacology

Inflawell improves neutrophil-to-lymphocyte ratio and shortens hospitalization in patients with moderate COVID-19, in a randomized double-blind placebo-controlled clinical trial.

Authors

Barzin Tond S, Balenci L, Khajavirad N, Salehi M R, Tafakhori A, Shahmohammadi M R, Ghiasvand F, Jafari S, Abolghasemi S, Mokhtari F, Mahmoodi Baram S, Zarei T, Kazemi D, Mohammadnejad E, Shah-Hosseini A, Haghbin Toutounchi A, Fallah S, Riazi A, Karima S
Inflammopharmacology. 2022 Feb 24.
PMID: 35201518.

Abstract

COVID-19 is a significant global threat to public health. Despite the availability of vaccines and anti-viral drugs, there is an urgent need for alternative treatments to help prevent and/or manage COVID-19 symptoms and the underlying dysregulated immune response. We hypothesized that administration of Inflawell syrup, a Boswellia extract formulation enriched for boswellic acids (BAs), can reduce the excessive or persistent inflammation and thereby prevent disease progression. BAs are medicinally activated triterpenoids found in the resins of Boswellia spp., and possess an immense therapeutic potential due to their anti-inflammatory and immunoregulatory activities. We investigated the effect of Inflawell syrup, on moderate COVID-19 patients along with the current standard of care treatment.